Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707) Notes Receivable: ¥0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603707 Nanjing King-Friend Biochemical Pharmaceutical Co Ltd SHSE:603707
65 GF Score
Price ¥7.55
GF Value ¥12.70
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Nanjing King-Friend Biochemical Pharmaceutical Co Notes Receivable?

Nanjing King-Friend Biochemical Pharmaceutical Co SHSE:603707 -4.07% 65 Notes Receivable is ¥0 Mil as of Mar. 2026. GuruFocus rates SHSE:603707 with a GF Score™ of 65/100 and a GF Value™ of ¥12.70 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Nanjing King-Friend Biochemical Pharmaceutical Co's Notes Receivable for the quarter that ended in Mar. 2026 was ¥0 Mil.

Nanjing King-Friend Biochemical Pharmaceutical Co Notes Receivable Related Terms

Nanjing King-Friend Biochemical Pharmaceutical Co Notes Receivable Historical Data

* Premium members only.

The historical data trend for Nanjing King-Friend Biochemical Pharmaceutical Co's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanjing King-Friend Biochemical Pharmaceutical Co Notes Receivable Chart

Nanjing King-Friend Biochemical Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Nanjing King-Friend Biochemical Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SHSE:603707
65GF Score
Nanjing King-Friend Biochemical Pharmaceutical Co Ltd SHSE:603707
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nanjing King-Friend Biochemical Pharmaceutical Co Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of ¥0 Mil mean?
Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707) has a Notes Receivable of ¥0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Nanjing King-Friend Biochemical Pharmaceutical Co and its competitors.
Is Nanjing King-Friend Biochemical Pharmaceutical Co's Notes Receivable too high?
Nanjing King-Friend Biochemical Pharmaceutical Co's current Notes Receivable is ¥0 Mil. Overall, Nanjing King-Friend Biochemical Pharmaceutical Co has a GF Score™ of 65/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nanjing King-Friend Biochemical Pharmaceutical Co's Notes Receivable compare to ZTS and UTHR?
Nanjing King-Friend Biochemical Pharmaceutical Co's Notes Receivable of ¥0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Nanjing King-Friend Biochemical Pharmaceutical Co and its competitors. Nanjing King-Friend Biochemical Pharmaceutical Co's current Notes Receivable is ¥0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanjing King-Friend Biochemical Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥12.70, compared to a current price of ¥7.55 — trading 40.6% below its estimated fair value. The current Notes Receivable is ¥0 Mil. Nanjing King-Friend Biochemical Pharmaceutical Co's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707), the current Notes Receivable is ¥0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707) Overvalued in 2026?

Based on GuruFocus' analysis, Nanjing King-Friend Biochemical Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥7.55 is trading 40.6% below its estimated GF Value™ of ¥12.70. GuruFocus considers Nanjing King-Friend Biochemical Pharmaceutical Co to be Significantly Undervalued.

Key valuation signals for SHSE:603707:

  • Notes Receivable: ¥0 Mil
  • GF Value™: ¥12.70 vs. price of ¥7.55 (40.6% below fair value)
  • GF Score™: 65/100 with 4 warning signs

No single metric tells the full story. See the SHSE:603707 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nanjing King-Friend Biochemical Pharmaceutical Co Business Description

Address 1/16 Xuefu Road, Nanjing High-Tech Zone, Nanjing, CHN, 210061
Nanjing King-Friend Biochemical Pharmaceutical Co Ltd is a China-based company engaged in the research and development, import and export of medicines and health products. The main products of the company are Heparin sodium and low molecular weight heparin. Geographically, the business activities are carried out through China and it exports the product mainly to the European and American countries.
65GF Score

Get the complete analysis for SHSE:603707

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥7.55
Price
¥12.70
GF Value